Residual Disease
10
2
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
Effective Treatments for Dizziness After BPPV: A Clinical Study
R0 Resection Rate Between CSP, cEMR and hEMR for 1-2 cm Colorectal SSLs
Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis